Neuralstem, Inc. (CUR)
(Delayed Data from NSDQ)
$0.52 USD
+0.02 (3.82%)
Updated May 3, 2019 04:13 PM ET
After-Market: $0.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Palisade Bio, Inc. [CUR]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: Roth Capital Partners, Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of CUR to Michael Higgins and placing shares Under Review
Provider: Roth Capital Partners, Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Major Data Not That Far Off for a Biotech
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Focused, Moving Forward, and Raising Funds Make Us Feel Good
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Strong Reset with NSI-189 Running the Show; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Neuralstem, Inc. under review due to the departure from the firm of the covering analyst.
Provider: H.C. Wainwright & Co., Inc.
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
New Leadership Places Priority on Differentiated Anti-Depressant
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Update: Strategic Refocusing Boosts Priority for Small Molecule Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Update-Depression Trial Could Wash Away the ALS Blues
Provider: H.C. Wainwright & Co., Inc.
Analyst: BREIDENBACH M
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Update-Prepping for the Next Phase 2 ALS Trial
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Update - Phase 2 ALS Results Show Efficacy in a Subset
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J
Company: Palisade Bio, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J